



DISCLOSURES AND RESOLUTION OF CONFLICT OF INTEREST

The following faculty members have indicated that they do have relevant financial relationships with ineligible companies* to disclose.

Directors and Planners

Manmeet Ahluwalia, M.D., faculty and planner of this educational activity, is a researcher for AstraZeneca, Bayer, Bristol–Myers Squibb, Incyte, Merck, Mimivax, Novocure and Pharmacyclics. He is a consultant for Apollomics, Bayer, Caris Life Sciences, Cellularity, GSK, Insightec, Janssen, Kiyatec, Novocure, Prelude, Pyramid Biosciences, SDP Oncology, Tocagen, Viewray, Voyager Therapeutics, Xoft, Varian Medical System and CAIRIN Therapeutics. He has individual stocks/stock options with Cytodyn, Doctible, Medinnovate Advisors LLC, and Mimivax. He has indicated that the presentation or discussions will not include off-label or unapproved product usage.

Rupesh Kotecha, M.D., faculty and planner for this educational activity, is a researcher for Medtronic, Blue Earth Diagnostics, Novocure, GT Medical Technologies, AstraZeneca, Exelixis, Viewray and Brainlab, consultant with Accuray, Elekta AB, Viewray, Novocure, Elsevier and Brainlab, a speaker with Novovure. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Michael McDermott, M.D., faculty and planner for this educational activity, is a consultant with Deide, Stryker, Insightec, and ZAP Surgical. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Minesh Mehta, M.D., faculty and planner for this educational activity, is a consultant with Karyopharm, Mevion, Sapience and Xoft. He has an executive role with Oncoceutics BOD and has individual stocks/stock options with Chimerix. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Yazmin Odia, M.D., faculty and planner for this educational activity, is a researcher with Novocure and trial support with Bristol-Myers Squibb, she is a consultant with Istari Oncology is on the scientific safety monitoring board with Gammatile GT. She has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Symposium Faculty

Priscilla Brastianos, M.D., faculty for this educational activity, is a researcher with Bristol-Myers Squib, Eli Lilly, Merck, Mirati Therapeutics and Kinnate Therapeutics and has received funding through MGH. She is also a consultant with SK Lifesciences, Voyager Therapeutics, Sintetica, ACI, Pfizer and Axiom, a member of the advisory board for Dantari Pharmaceuticals and a speaker with Pfizer. She has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Veronica Chiang, M.D., faculty for this educational activity has no relevant financial relationships with ineligible companies* to disclose, and has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Antonio Chiocca, M.D., Ph.D., faculty for this educational activity, is an advisor with Amacathera, Bionaut Labs, Candel Therapeutics, Genenta, Insightec, DNATRIX, Seneca Therapeutics, Synthetic Biologics, Alcyone, Amasa, Bexion, Biogen, GSK Oncorus, Merck, Tocagen, Ziopharm, Stamgen, Nano Tx, Ziopharm Oncology, Cerebral Therapeutics, Ceregene, GSK, Janssen, Karcinolysis, Shanghai Biotech, Sangamo Therapeutics and Voyager Therapeutics, he has stock options with Bionaut Laboratories, DNATRIX, Immunomic Therapeutics, Seneca Therapeutics, Synthetic Biologics and Ternalys

Therapeutics. He is Co-founder of Termalys Therapeutics named co-inventor on patents related to oncolytic HSV1 and noncoding RNS's without royalties.

Vinai Gondi, M.D., faculty for this educational activity, is a researcher with ImmunoChem Therapeutics, LLC and is an employee of Radiation Oncology Consultants. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Matthew Hall, M.D., faculty for this educational activity, has an executive role with Proton Collaborative Group (PCG) and is an executive representative for MCI (unpaid). He has received an honorarium from IBA Inc. – Proton therapy Arc Talk at NAPT. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Fabio Iwamoto, M.D., faculty for this educational activity, is a researcher with Bristol-Myers Squibb, Celldex, FORMA Therapeutics, Merck, Northwest Biotherapeutics, Novocure, Sapience Therapeutics and Tocagen. He is a consultant with Abbvie, Alexion Pharmaceuticals, Gennao Bio, Guidepoint Global, Kiyatec, Massive Bio, Medtronic, Merck, Mimivax, Novocure, PPD, Regeneron, Tocagen and Xcures. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Stephen Mack, Ph.D., faculty for this educational activity has no relevant financial relationships with ineligible companies* to disclose, and has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Roger Stupp, M.D., faculty for this educational activity, is a researcher with Carthera and Bristol Myers Squibb and a speaker for Carthera and an advisor for Alpheus Medical, AstraZeneca, Boston Scientific, Carthera, Celularity, GT Medical, Insightec, Lockwood, Northwest Biotherapeutics, Novocure, Syneos Health, TriAct Therapeutics and Varian Medical Systems. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Patrick Wen, M.D., faculty for this educational activity, is a researcher with AstraZeneca, BeiGene, Bristol-Myers Squibb, Chimerix, Eli Lilly, Erasca, Kazia, MedicNova, Merck, Novartis, Nuvation Bio, Puma, Servier, Vascular Biogenics and VBI Vaccines. He is an adviser for Astra Zeneca, Bayer, Black Diamond, Boehringer Ingelheim, Boston Pharmaceuticals, Celularity, Chimerix, Day One Bio, Genenta, Glaxode Therapeutics, Sapeience, Servier, Sagiment, Vascular Biogenics and VBI Vaccines. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

All of the relevant financial relationships listed for these individuals have been mitigated.

Other individuals involved in planning, content review, approval, or moderating for this educational activity have no relevant financial relationships to disclose with ineligible companies*.

**Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.*